Help Unlock the Aerie Match

by ASCRS Foundation

Help unlock the $30,000 from Aerie Pharmaceuticals for the ASCRS Foundation

Since 2018, Aerie Pharmaceuticals has challenged attendees at the ASCRS Annual Meeting to give to unlock a matched donation for the ASCRS Foundation. In just two years, your generosity has restored the sight of more than 460 patients by meeting the challenge. Aerie unwavering philanthropic commitment to our mission is continuing in 2020 by continuing their match. Your donation will be doubled up to $30,000! 

This match comes at a crucial time. Over 4,500 charitable surgeries have been provided to patients in need in their own communities through our volunteer network and the Operation Sight program. We continue to screen patients and accept applications and anticipate the number of patients who will qualify for Operation Sight to dramatically increase as the unemployment rate rises across the country. For many patients, surgery will give them not only the gift of sight, but the key to regaining employment to provide for their families. Should you know of a patient who may qualify, please refer them to our patient information page

Your gift will have an ever-lasting impact on someone’s future. 

Donation Information
The American Society of Cataract and Refractive Surgery Foundation is a 501(c)3 tax-exempt organization (EIN: 23-7388748) and donations are tax deductible. Donations made up to $30,000 will be doubled. Donations may also be made by visiting

For additional ways to give, please click here or contact contact Molly Gascoigne, Director of Development, ASCRS Foundation at

About the ASCRS Foundation:
The ASCRS Foundation supports physician education and provides humanitarian cataract surgery in the United States and developing countries. Through its programs and partnerships, the Foundation works to maximize the benefits of modern ophthalmology and to treat thousands of patients in need each year. Learn more at

About Aerie Pharmaceuticals:
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye.

Make A Donation